Literature DB >> 12519386

Butyrate modulates intestinal epithelial cell-mediated neutrophil migration.

U Böcker1, T Nebe, F Herweck, L Holt, A Panja, C Jobin, S Rossol, R B Sartor, M V Singer.   

Abstract

Butyrate, a short-chain fatty acid released by colonic bacteria and administered therapeutically in inflammatory bowel diseases, exerts immunomodulatory properties. The aim of the study was to determine the functional consequences of butyrate exposure on the proinflammatory responsiveness of human intestinal epithelial cells (IEC). IL-8 promoter activity in IEC pretreated with butyrate then exposed to proinflammatory stimuli was assayed by transfection of luciferase constructs. IL-8 secretion was determined by ELISA and neutrophil migration by flow cytometry. Receptor mRNA was assessed by reverse transcriptase-polymerase chain reaction (RT-PCR). Butyrate modulated proinflammatory IL-8 secretion differentially in Caco-2 and HT-29 cells on the transcriptional level. Pointing to the potentially underlying mechanism of increased IL-1 beta-stimulated IL-8 secretion in HT-29 cells, butyrate up-regulated IL-1RI mRNA but not IL-1RII. Butyrate pretreatment of IEC lines stimulated by IL-1 beta modulated neutrophil migration significantly: reduction towards Caco-2 and enhancement towards HT-29/p cells. Pharmacological inhibition of protein tyrosine phosphatases or treatment with mesalamine or sulphasalazine diminished IL-1 beta-stimulated IL-8 secretion by butyrate-exposed HT-29 cells substantially. Immunomodulatory effects of butyrate on IEC are functionally relevant for neutrophil migration. Pharmacological inhibition of enhanced IL-1 beta-mediated IL-8 secretion in a subpopulation of IEC may improve the clinical efficacy of butyrate.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12519386      PMCID: PMC1808611          DOI: 10.1046/j.1365-2249.2003.02056.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  32 in total

1.  A novel method for the establishment of a pure population of nontransformed human intestinal primary epithelial cell (HIPEC) lines in long term culture.

Authors:  A Panja
Journal:  Lab Invest       Date:  2000-09       Impact factor: 5.662

2.  Treatment of left-sided ulcerative colitis with butyrate enemas: a controlled trial.

Authors:  A H Steinhart; T Hiruki; A Brzezinski; J P Baker
Journal:  Aliment Pharmacol Ther       Date:  1996-10       Impact factor: 8.171

Review 3.  The role of interleukin-1 in disease.

Authors:  C A Dinarello; S M Wolff
Journal:  N Engl J Med       Date:  1993-01-14       Impact factor: 91.245

4.  The effect of sodium butyrate on histone modification.

Authors:  L Sealy; R Chalkley
Journal:  Cell       Date:  1978-05       Impact factor: 41.582

5.  Butyrate switches the pattern of chemokine secretion by intestinal epithelial cells through histone acetylation.

Authors:  R D Fusunyan; J J Quinn; M Fujimoto; R P MacDermott; I R Sanderson
Journal:  Mol Med       Date:  1999-09       Impact factor: 6.354

6.  Growth adaptation to methotrexate of HT-29 human colon carcinoma cells is associated with their ability to differentiate into columnar absorptive and mucus-secreting cells.

Authors:  T Lesuffleur; A Barbat; E Dussaulx; A Zweibaum
Journal:  Cancer Res       Date:  1990-10-01       Impact factor: 12.701

7.  Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4.

Authors:  F Colotta; F Re; M Muzio; R Bertini; N Polentarutti; M Sironi; J G Giri; S K Dower; J E Sims; A Mantovani
Journal:  Science       Date:  1993-07-23       Impact factor: 47.728

8.  Differential effects of sodium butyrate, dimethyl sulfoxide, and retinoic acid on membrane-associated antigen, enzymes, and glycoproteins of human rectal adenocarcinoma cells.

Authors:  D Tsao; A Morita; A Bella; P Luu; Y S Kim
Journal:  Cancer Res       Date:  1982-03       Impact factor: 12.701

9.  Emergence of permanently differentiated cell clones in a human colonic cancer cell line in culture after treatment with sodium butyrate.

Authors:  C Augeron; C L Laboisse
Journal:  Cancer Res       Date:  1984-09       Impact factor: 12.701

10.  Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man.

Authors:  W E Roediger
Journal:  Gut       Date:  1980-09       Impact factor: 23.059

View more
  30 in total

Review 1.  Gut microbiota-immune-brain interactions in chemotherapy-associated behavioral comorbidities.

Authors:  Kelley R Jordan; Brett R Loman; Michael T Bailey; Leah M Pyter
Journal:  Cancer       Date:  2018-07-05       Impact factor: 6.860

Review 2.  Butyrate: A Double-Edged Sword for Health?

Authors:  Hu Liu; Ji Wang; Ting He; Sage Becker; Guolong Zhang; Defa Li; Xi Ma
Journal:  Adv Nutr       Date:  2018-01-01       Impact factor: 8.701

3.  Effect of short-chain fatty acids on the expression of genes involved in short-chain fatty acid transporters and inflammatory response in goat jejunum epithelial cells.

Authors:  Kang Zhan; MaoCheng Jiang; Xiaoxiao Gong; GuoQi Zhao
Journal:  In Vitro Cell Dev Biol Anim       Date:  2018-03-12       Impact factor: 2.416

4.  Development of a bread delivery vehicle for dietary prebiotics to enhance food functionality targeted at those with metabolic syndrome.

Authors:  Adele Costabile; Gemma E Walton; George Tzortzis; Jelena Vulevic; Dimitris Charalampopoulos; Glenn R Gibson
Journal:  Gut Microbes       Date:  2015-06-22

5.  Short-chain fatty acids act as antiinflammatory mediators by regulating prostaglandin E(2) and cytokines.

Authors:  Mary Ann Cox; James Jackson; Michaela Stanton; Alberto Rojas-Triana; Loretta Bober; Maureen Laverty; Xiaoxin Yang; Feng Zhu; Jianjun Liu; Suke Wang; Frederick Monsma; Galya Vassileva; Maureen Maguire; Eric Gustafson; Marvin Bayne; Chuan-Chu Chou; Daniel Lundell; Chung-Her Jenh
Journal:  World J Gastroenterol       Date:  2009-11-28       Impact factor: 5.742

Review 6.  The Role of the Microbial Metabolites Including Tryptophan Catabolites and Short Chain Fatty Acids in the Pathophysiology of Immune-Inflammatory and Neuroimmune Disease.

Authors:  Gerwyn Morris; Michael Berk; Andre Carvalho; Javier R Caso; Yolanda Sanz; Ken Walder; Michael Maes
Journal:  Mol Neurobiol       Date:  2016-06-27       Impact factor: 5.590

Review 7.  The athletic gut microbiota.

Authors:  Alex E Mohr; Ralf Jäger; Katie C Carpenter; Chad M Kerksick; Martin Purpura; Jeremy R Townsend; Nicholas P West; Katherine Black; Michael Gleeson; David B Pyne; Shawn D Wells; Shawn M Arent; Richard B Kreider; Bill I Campbell; Laurent Bannock; Jonathan Scheiman; Craig J Wissent; Marco Pane; Douglas S Kalman; Jamie N Pugh; Carmen P Ortega-Santos; Jessica A Ter Haar; Paul J Arciero; Jose Antonio
Journal:  J Int Soc Sports Nutr       Date:  2020-05-12       Impact factor: 5.150

8.  Effect of interleukin-1β on ICAM-1 expression of dental pulp cells: role of PI3K/Akt, MEK/ERK, and cyclooxygenase.

Authors:  Mei-Chi Chang; Hsiu-Pin Hung; Li-Deh Lin; Yow-Chyun Shyu; Tong-Mei Wang; Hsueh-Jen Lin; Chiu-Po Chan; Chih-Chia Huang; Jiiang-Huei Jeng
Journal:  Clin Oral Investig       Date:  2014-03-20       Impact factor: 3.573

9.  A randomised, double-blind, placebo controlled cross-over study to determine the gastrointestinal effects of consumption of arabinoxylan-oligosaccharides enriched bread in healthy volunteers.

Authors:  Gemma E Walton; Congyi Lu; Isabel Trogh; Filip Arnaut; Glenn R Gibson
Journal:  Nutr J       Date:  2012-06-01       Impact factor: 3.271

10.  PGE2 induces interleukin-8 derepression in human astrocytoma through coordinated DNA demethylation and histone hyperacetylation.

Authors:  Isabella Venza; Maria Visalli; Cinzia Fortunato; Manuela Ruggeri; Simona Ratone; Maria Caffo; Gerardo Caruso; Concetta Alafaci; Francesco Tomasello; Diana Teti; Mario Venza
Journal:  Epigenetics       Date:  2012-10-10       Impact factor: 4.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.